Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07280221 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

WEgovy Real World Assessment of Weight Loss in Korea

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Novo Nordisk A/S to Novo Nordisk A/S
    • Trial sites expanded: 1 → 18 locations
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 10 of 29 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novo Nordisk
268 trials monitored
See 15 trials at risk
Obesity
3,874 trials monitored
See 152 trials at risk
This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.
Trial Details
NCT Number NCT07280221
Lead Sponsor Novo Nordisk A/S
Conditions
(from sponsor)		 Obesity
Related terms Obesity
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov